A Phase 2 interventional study of G001 Topical Gel and Vehicle in Osteoarthritis, Knee, sponsored by BUZZZ Pharmaceuticals Limited. Completed at 10 sites in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by BUZZZ Pharmaceuticals Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Osteoarthritis, Knee with a site in Canada — 28 open to participants now, 41 under way, 6 of them phase 3. Osteoarthritis, Knee · Canada.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, this one is the 29th largest by enrollment of the 160 interventional ones that give a count, is one of 9 that started in 2021, is one of 19 in phase 2, and was the 120th registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →28 of the 171 studies in Osteoarthritis, Knee with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Canada, United States, Australia and 7 more countries
Ages 18+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 40–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 29 · Phase 3 25 · Phase 4 10
First in 1999; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 68 across 2,716 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 65 across the 160 interventional studies, 48 across the 10 observational. Of the 105 that completed or were terminated, 29 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 171 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with BUZZZ Pharmaceuticals Limited as lead sponsor.
BUZZZ Pharmaceuticals Limited has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
14 of the studies in Osteoarthritis, Knee with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05283889University of CalgaryGenicular Radiofrequency Ablation Following Total Knee Arthroplasty | 2026-12 |
| NCT04378049McMaster UniversityRobot-Assisted Partial Knee Replacement Versus Standard Total Knee Replacement | 2026-12 |
| NCT01674816Centre hospitalier de l'Université de Montréal (CHUM)Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration | 2026-12-01 |
| NCT06166628David ClinkardGenicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis | 2026-12-01 |
| NCT06195423University of British ColumbiaStopping OsteoARthritis After an ACL Tear | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 171 studies in Osteoarthritis, Knee with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2 multicenter, double-blind, randomized, parallel-group, vehicle-controlled study to evaluate the efficacy, safety, and local tolerability of G001 topical gel compared to matching Vehicle topical gel in patients with symptomatic OA of the knee.
Each patient's participation is approximately 7 weeks (\~1 week screening, 4 weeks of treatment, and 2 weeks of post-treatment follow-up). Eligible patients with adequate OA pain in the index knee are randomized (1:1 allocation ratio) at the Baseline/Flare Visit 1.
Following screening, prior NSAID and/or acetaminophen use is discontinued to allow for washout and symptom flare. Patients are instructed to rate their worst daily and nightly pain in their daily diary, as well as to document all study drug applications and any rescue medication (acetaminophen) use for breakthrough pain. Acetaminophen may be used as rescue medication only, except within 12 hours prior to the Baseline Visit and within 12 hours prior to any post-baseline efficacy assessments (Weeks 2, 4, and 5). Patients are instructed to return to the clinic 3 to 7 days after the last study drug application for Flare Visit 2, and within approximately 2 weeks after the last study drug application for end-of-study evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At Baseline:
Exclusion Criteria:
At Baseline:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
G001 Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
Drug: G001 Topical Gel
Vehicle Topical Gel, 4 grams applied to the index knee four times a day over 4 weeks.
Drug: Vehicle
Non-steroidal anti-inflammatory drug for topical administration
Vehicle Gel for topical administration
Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT
Changes from Baseline in WOMAC Pain Subscale Score (5-item scale, score range 0-20, with higher scores indicating worse outcome)
Time frame: Week 4
Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings
Changes from Baseline to Week 4 in Worst Daytime Pain Severity Scores on a 0-10 scale, with higher scores indicating worse outcome
Time frame: Week 4
Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings
Changes from Baseline to Week 4 in Worst Nighttime Pain Severity Scores recorded on a 0-10 scale, with higher scores indicating worse outcome
Time frame: Week 4
Percent Reduction From Baseline in Worst Daytime Pain
Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Daytime Pain at Week 4/EOT
Time frame: Week 4
Percent Reduction From Baseline in Worst Nighttime Pain
Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Nighttime Pain at Week 4/EOT
Time frame: Week 4
Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT
WOMAC Physical Function Subscale (17-item, score range 0-68, with higher scores indicating worse outcome)
Time frame: Week 4
Change From Baseline in WOMAC Total Score at Week 4/EOT
WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome)
Time frame: Week 4
Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT
WOMAC Stiffness Subscale (2-item, range of scores 0-8, with higher scores indicating worse outcome)
Time frame: Week 4
Change From Baseline in WOMAC Total and Subscale Scores at Week 2
Change from Baseline to Week 2 in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)
Time frame: Week 2
Change From Week 4 to Week 5 in WOMAC Total and Subscale Scores
Change from Week 4/EOT to Week 5/Flare Visit 2 (FV2) in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)
Time frame: Week 4 to Week 5
Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Over Time
PGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in PGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened
Time frame: Weeks 2, 4 and 5
Change From Baseline in Investigator Global Assessment (IGA) of Disease Activity Over Time
IGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in IGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened
Time frame: Weeks 2, 4 and 5
PGA of Overall Treatment Benefit (OTB)
PGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.
Time frame: Weeks 2 and 4
IGA of Overall Treatment Benefit (OTB)
IGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.
Time frame: Weeks 2 and 4
Rescue Medication Use
Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.
Time frame: 5 weeks
Number of Rescue Medication Doses
Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.
Time frame: 5 weeks
Number of Participants With AEs, Study Drug-related AEs, Serious AEs, and AEs Leading to Study Drug Discontinuation
Number and percentage of participants with adverse events (AEs), study drug-related AEs, serious AEs, and AEs leading to study drug discontinuation
Time frame: 6 weeks
Frequency and Severity of Application Site AEs
Number and percentage of participants with application site AEs
Time frame: 6 weeks
Skin Irritation Test Scores (Berger/Bowman Scoring Scale)
The Numerical Total Score is the sum of the Dermal Response score (from 0=No evidence of irritation to 7=Strong reaction spreading beyond the application site) and the numeric equivalent of Other Effects score (from 0=Slightly glazed appearance to 3=Small petechial erosions and/or scabs). The Numerical Total Score range is from 0 to 10, with higher scores indicating worse outcome/skin irritation.
Time frame: Weeks 2, 4, and 6
ECG Abnormalities in QT, QTc, QRS, or PR Intervals
Number and percentage of participants with clinically significant (CS) abnormal results in QT, QTc, QRS, or PR intervals at Week 4/EOT
Time frame: 4 weeks
Changes From Baseline in Safety Laboratory Test Results
Mean changes (descriptive) and shifts from normal baseline to laboratory values outside reference ranges
Time frame: 6 weeks
Changes in Vital Signs Measurements
Mean changes (descriptive) from baseline
Time frame: 6 weeks
Changes in Physical Examination
Number and percentage of participants with clinically significant abnormal findings
Time frame: 6 weeks
The study was conducted at 10 study centers in Canada. A total of 210 patients with OA of the knee were randomly assigned to double-blinded treatment in the study; of these, 105 patients received G001 and 105 patients received Vehicle.
| Milestone | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Started | 105 | 105 |
| Completed | 99 | 100 |
| Not completed | 6 | 5 |
Changes from Baseline in WOMAC Pain Subscale Score (5-item scale, score range 0-20, with higher scores indicating worse outcome)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Change From Baseline in WOMAC Pain Subscale Score at Week 4/EOT | -5.4 ± 0.32 | -5.2 ± 0.32 |
Changes from Baseline to Week 4 in Worst Daytime Pain Severity Scores on a 0-10 scale, with higher scores indicating worse outcome
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Worst Daytime Pain Severity Scores (11-point Pain NRS), Based on Daily Diary Recordings | -2.1 ± 2.01 | -2.0 ± 2.07 |
Changes from Baseline to Week 4 in Worst Nighttime Pain Severity Scores recorded on a 0-10 scale, with higher scores indicating worse outcome
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Worst Nighttime Pain Severity Score (11-point NRS), Based on Daily Diary Recordings | -2.1 ± 2.01 | -1.9 ± 2.04 |
Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Daytime Pain at Week 4/EOT
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| ≥ 20% Reduction from BL | 70 | 68 |
| ≥ 30% Reduction from BL | 58 | 53 |
| ≥ 50% Reduction from BL | 35 | 36 |
Percentage of Patients Achieving ≥ 20%, ≥ 30%, and ≥ 50% Reduction from Baseline in Worst Nighttime Pain at Week 4/EOT
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| ≥ 20% Reduction from BL | 73 | 65 |
| ≥ 30% Reduction from BL | 59 | 56 |
| ≥ 50% Reduction from BL | 36 | 35 |
WOMAC Physical Function Subscale (17-item, score range 0-68, with higher scores indicating worse outcome)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Change From Baseline in WOMAC Physical Function Subscale Score at Week 4/EOT | -12.5 ± 1.07 | -10.4 ± 1.06 |
WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Change From Baseline in WOMAC Total Score at Week 4/EOT | -19.4 ± 1.47 | -17.1 ± 1.46 |
WOMAC Stiffness Subscale (2-item, range of scores 0-8, with higher scores indicating worse outcome)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Change From Baseline in WOMAC Stiffness Subscale Score at Week 4/EOT | -1.6 ± 0.14 | -1.5 ± 0.14 |
Change from Baseline to Week 2 in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| WOMAC Total score, Change from BL to Week 2 | -15.7 ± 1.27 | -13.2 ± 1.25 |
| WOMAC Pain score, Change from BL to Week 2 | -4.7 ± 0.29 | -4.4 ± 0.29 |
| WOMAC Stiffness score, Change from BL to Week 2 | -1.4 ± 0.13 | -1.0 ± 0.13 |
| WOMAC Physical Function score, Change from BL to Week 2 | -9.5 ± 0.93 | -8.0 ± 0.91 |
Change from Week 4/EOT to Week 5/Flare Visit 2 (FV2) in: WOMAC Osteoarthritis Index Total score (24-item, score range 0-96, with higher scores indicating worse outcome) WOMAC Pain Subscale score (5-item, score range 0-20, with higher scores indicating worse pain) WOMAC Stiffness Subscale score (2-item, score range 0-8, with higher scores indicating worse stiffness) WOMAC Physical Function Subscale score (17-item, score range 0-68, with higher scores indicating worse physical function)
| score on a scale | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| WOMAC Total score, Change from Week 4/EOT to Week 5/FV2 | 3.5 ± 0.89 | 2.7 ± 0.89 |
| WOMAC Pain score, Change from Week 4/EOT to Week 5/FV2 | 0.8 ± 0.21 | 0.7 ± 0.21 |
| WOMAC Stiffness score, Change from Week 4/EOT to Week 5/FV2 | 0.3 ± 0.10 | 0.3 ± 0.10 |
| WOMAC Physical Function score, Change from Week 4/EOT to Week 5/FV2 | 2.4 ± 0.65 | 1.7 ± 0.65 |
PGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in PGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| PGA of DA, Change from BL to Week 2 — Improved | 24 | 20 |
| PGA of DA, Change from BL to Week 2 — No change | 74 | 79 |
| PGA of DA, Change from BL to Week 2 — Worsened | 1 | 3 |
| PGA of DA, Change from BL to Week 4 — Improved | 38 | 28 |
| PGA of DA, Change from BL to Week 4 — No change | 64 | 72 |
| PGA of DA, Change from BL to Week 4 — Worsened | 0 | 4 |
| PGA of DA, Change from BL to Week 5 — Improved | 26 | 21 |
| PGA of DA, Change from BL to Week 5 — No change | 73 | 75 |
| PGA of DA, Change from BL to Week 5 — Worsened | 1 | 4 |
IGA of Disease Activity (DA) was assessed on a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor), with higher scores indicating worse outcome. Change from Baseline in IGA of disease activity scores was calculated and the response was classified into 3 categories according to the following rules: Improved - defined as either of the following: * For baseline Grade ≥ 2: a reduction of ≥ 2 grades from baseline * For baseline Grade = 1: a change in grade from 1 to 0 Worsened - defined as either of the following: * For baseline Grade ≤ 2: an increase of ≥ 2 grades from baseline * For baseline Grade = 3: a change in grade from 3 to 4 No Change - defined as neither Improved nor Worsened
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| IGA of DA, Change from BL to Week 2 — Improved | 24 | 22 |
| IGA of DA, Change from BL to Week 2 — No Change | 74 | 77 |
| IGA of DA, Change from BL to Week 2 — Worsened | 1 | 3 |
| IGA of DA, Change from BL to Week 4 — Improved | 39 | 29 |
| IGA of DA, Change from BL to Week 4 — No Change | 63 | 72 |
| IGA of DA, Change from BL to Week 4 — Worsened | 1 | 3 |
| IGA of DA, Change from BL to Week 5 — Improved | 30 | 21 |
| IGA of DA, Change from BL to Week 5 — No Change | 67 | 78 |
| IGA of DA, Change from BL to Week 5 — Worsened | 3 | 1 |
PGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| PGA of OTB at Week 2 — Good or Very Good | 32 | 39 |
| PGA of OTB at Week 2 — Fair | 49 | 47 |
| PGA of OTB at Week 2 — Poor or Very Poor | 18 | 16 |
| PGA of OTB at Week 4 — Good or Very Good | 50 | 46 |
| PGA of OTB at Week 4 — Fair | 36 | 38 |
| PGA of OTB at Week 4 — Poor or Very Poor | 16 | 20 |
IGA of overall treatment benefit was completed using a 5-point Likert scale (0 = very good; 1 = good; 2 = fair; 3 = poor; and 4 = very poor) after 2 and 4 weeks of treatment, with higher scores indicating worse outcome.
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| IGA of OTB, Week 2 — Very Good or Good | 32 | 40 |
| IGA of OTB, Week 2 — Fair | 47 | 47 |
| IGA of OTB, Week 2 — Poor or Very Poor | 20 | 15 |
| IGA of OTB, Week 4 — Very Good or Good | 52 | 46 |
| IGA of OTB, Week 4 — Fair | 35 | 39 |
| IGA of OTB, Week 4 — Poor or Very Poor | 16 | 19 |
Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.
| mg/day | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Rescue Medication Use | 71.6 ± 66.65 | 94.6 ± 123.3 |
Number and percentage of participants with adverse events (AEs), study drug-related AEs, serious AEs, and AEs leading to study drug discontinuation
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Any TEAE | 36 | 28 |
| Treatment-related TEAEs | 5 | 4 |
| Any SAE | 0 | 1 |
| Any TEAE leading to Discontinuation | 3 | 1 |
Number and percentage of participants with application site AEs
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Frequency and Severity of Application Site AEs | 0 | 1 |
The Numerical Total Score is the sum of the Dermal Response score (from 0=No evidence of irritation to 7=Strong reaction spreading beyond the application site) and the numeric equivalent of Other Effects score (from 0=Slightly glazed appearance to 3=Small petechial erosions and/or scabs). The Numerical Total Score range is from 0 to 10, with higher scores indicating worse outcome/skin irritation.
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Skin Irritation Total Score, Week 2 — Numerical Total Score of 0 | 98 | 101 |
| Skin Irritation Total Score, Week 2 — Numerical Total Score of 1 | 1 | 0 |
| Skin Irritation Total Score, Week 2 — Numerical Total Score of ≥2 | 1 | 1 |
| Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of 0 | 101 | 103 |
| Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of 1 | 1 | 1 |
| Skin Irritation Total Score, Week 4/EOT — Numerical Total Score of ≥2 | 1 | 0 |
| Skin Irritation Total Score, Week 6 — Numerical Total Score of 0 | 101 | 101 |
| Skin Irritation Total Score, Week 6 — Numerical Total Score of 1 | 0 | 0 |
| Skin Irritation Total Score, Week 6 — Numerical Total Score of ≥2 | 0 | 0 |
Number and percentage of participants with clinically significant (CS) abnormal results in QT, QTc, QRS, or PR intervals at Week 4/EOT
| Participants | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| CS QT Interval abnormality | 0 | 0 |
| CS QTc Interval abnormality | 0 | 0 |
| CS QRS Interval abnormality | 0 | 0 |
| CS PR Interval abnormality | 0 | 0 |
Mean changes (descriptive) and shifts from normal baseline to laboratory values outside reference ranges
Results for this outcome have not been posted.
Mean changes (descriptive) from baseline
Results for this outcome have not been posted.
Number and percentage of participants with clinically significant abnormal findings
Results for this outcome have not been posted.
Only acetaminophen was permitted as rescue medication (up to 500 mg per dose and 2000 mg/day to manage breakthrough pain). No rescue medication use was allowed within 12 hours before an efficacy assessment.
| number of doses | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Number of Rescue Medication Doses | 5.9 ± 6.03 | 7.9 ± 12.54 |
Collected over Adverse event (AE) collection period: from the Screening Visit (Day -7 to -3) to the Week 6/End-of-Study (EOS) Visit (Day 43 +/-3). Analyses of AEs were performed for treatment-emergent events (TEAEs), defined as any AE with onset during or after the first application of study drug through the end of the study (Week 6/EOS visit), or any event that was present at Baseline but worsened in severity during or after the first application of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| G001 Topical Gel | 0/105 (0%) | 0/105 (0%) | 10/105 (9.5%) |
| Vehicle Topical Gel | 0/105 (0%) | 1/105 (1%) | 5/105 (4.8%) |
| Event | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/105 | 1/105 |
| Event | G001 Topical Gel | Vehicle Topical Gel |
|---|---|---|
| HeadacheNervous system disorders | 10/105 | 5/105 |
| Age, Continuous(years) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Mean | 64.3 ± 7.89 | 65.3 ± 8.35 | 64.8 ± 8.12 |
| Sex: Female, Male(Participants) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Female | 64 | 61 | 125 |
| Male | 41 | 44 | 85 |
| Ethnicity (NIH/OMB)(Participants) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 104 | 105 | 209 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 17 | 10 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 6 | 9 |
| White | 83 | 89 | 172 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Canada | 105 | 105 | 210 |
| Worst daily pain (11-point NRS), Index knee(Score on a scale) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Mean | 6.8 ± 1.29 | 6.4 ± 1.39 | 6.6 ± 1.35 |
| Worst daily pain (11-point NRS), Contralateral knee(Score on a scale) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| Mean | 1.1 ± 0.78 | 0.9 ± 0.81 | 1.0 ± 0.80 |
| Kellgren and Lawrence Grading(Participants) | G001 Topical Gel | Vehicle Topical Gel | Total |
|---|---|---|---|
| KL Grade 2 | 46 | 53 | 99 |
| KL Grade 3 | 59 | 52 | 111 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Jan 2023, 23 months.
Results were first posted in Apr 2024, 1 year 3 months after primary completion.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 23 months is above that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.